Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986453 |
Synonyms | |
Therapy Description |
Limited information is currently available on BMS-986453, a putative chimeric antigen receptor (CAR) T-cell therapy targeting TNFRSF17 (BCMA) and GPRC5D (Dec 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986453 | BMS986453|BMS 986453 | Limited information is currently available on BMS-986453, a putative chimeric antigen receptor (CAR) T-cell therapy targeting TNFRSF17 (BCMA) and GPRC5D (Dec 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06153251 | Phase I | BMS-986453 Cyclophosphamide + Fludarabine | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | DEU | 0 |